corticotropin releasing factor

Also found in: Wikipedia.
Related to corticotropin releasing factor: ACTH, Corticotropin releasing hormone

corticotro′pin releas′ing fac`tor

a hormonelike substance of the hypothalamus that increases the production of ACTH in response to stress. Abbr.: CRF
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
Chandler, "Corticotropin releasing factor dose-dependently modulates excitatory synaptic transmission in the noradrenergic nucleus locus coeruleus," European Journal of Neuroscience, vol.
Assenmacher, "Evidence for basal and stress-induced release of corticotropin releasing factor in the push-pull cannulated median eminence of conscious free-moving rats," Neuroscience Letters, vol.
A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice.
Thatcher-Britton, "Stimulant and anxiogenic effects of corticotropin releasing factor.," Progress in clinical and biological research, vol.
Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Corticotropin releasing factor (CRF) plays an important role during the development of alcohol addiction and stress-induced relapses to alcohol drinking (M.
Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
For example, the liver dysfunction causes impairment of proteins and amino acids metabolism, which interferes with the hormones production, such as corticotropin releasing factor (CRF) and glucocorticoids which are components of the hypothalamic-pituitary-adrenal (HPA) axis or stress axis and play an important role in central regulation of energy balance and food intake (RICHARD et al., 2002).
Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation.
Neurocrine Biosciences reported efficacy and safety results from a Phase II trial using Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients experiencing a major depressive episode.
Full browser ?